CAJ | 학술논문

目的探讨唑来膦酸对肺癌骨转移患者首次骨相关事件(SRE)的作用.方法回顾性分析2007年1月至2010年6月期间106例肺癌骨转移患者的临床资料.A组为未使用唑来膦酸病例67例(63.2％)；B组为骨转移后使用唑来膦酸治疗病例39例(36.8％),比较2组首次SRE的发生情况.结果 106例患者中50例(47.2％)患者发生首次SRE,A组的首次SRE发生率为56.7％ (38/67),明显高于B组[30.8％ (12/39)],2组比较差异有统计学意义(P＜0.05).其中,A组的骨放疗事件发生率明显高于B组[40.3％ (29/67)比20.5％ (8/39)],2组比较有统计学差异(P＜0.05).2组患者的中位无SRE生存时间分别为7.4和8.4个月.2组比较差异无统计学意义(P＞0.05).结论唑来膦酸能减少肺癌骨转移患者的首次SRE发生率,尤其减少骨放疗事件的发生.
목적 탐토서래련산대폐암골전이환자수차골상관사건(SRE)적작용.방법 회고성분석2007년1월지2010년6월기간106례폐암골전이환자적림상자료.A조위미사용서래련산병례67례(63.2％)；B조위골전이후사용서래련산치료병례39례(36.8％),비교2조수차SRE적발생정황.결과 106례환자중50례(47.2％)환자발생수차SRE,A조적수차SRE발생솔위56.7％ (38/67),명현고우B조[30.8％ (12/39)],2조비교차이유통계학의의(P＜0.05).기중,A조적골방료사건발생솔명현고우B조[40.3％ (29/67)비20.5％ (8/39)],2조비교유통계학차이(P＜0.05).2조환자적중위무SRE생존시간분별위7.4화8.4개월.2조비교차이무통계학의의(P＞0.05).결론 서래련산능감소폐암골전이환자적수차SRE발생솔,우기감소골방료사건적발생.
Objective To investigate the role of zoledronic acid in the treatment first skeletal related events (SRE) in lung cancer patients with bone metastases.Methods Clinical data of 106 patients in lung cancer with bone metastases and admitted from January 2007 to June 2003 were reviewed.There were 67 patients(63.2％ ) in A group who were treated without zoledronic acid and there were 39 patients (36.8％ ) in B group who were treated with oledronic acid.Results Of 106 patients,50 cases (47.2％ ) had first SRE.The rate of first SRE in A group was significantly higher than that in B group(56.7％ vs 30.8％,P ＜ 0.05 ).The incidence rate of radiation in A group was significantly higher than that in B group(40.3％ vs 20.5％,P ＜0.05).The median time to first SRE of two groups was 7.4 months and 8.4 months respectively; there was no significant difference ( P ＞ 0.05 ).Conclusion Zoledex is effective to reduce first SRE in non-small cell lung cancer patients with bone metastases,especially to reduce the incidence rates of radiation.